These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A DM1-doped porous gold nanoshell system for NIR accelerated redox-responsive release and triple modal imaging guided photothermal synergistic chemotherapy. Xu P; Wang R; Yang W; Liu Y; He D; Ye Z; Chen D; Ding Y; Tu J; Shen Y J Nanobiotechnology; 2021 Mar; 19(1):77. PubMed ID: 33741008 [TBL] [Abstract][Full Text] [Related]
3. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425 [TBL] [Abstract][Full Text] [Related]
4. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. McLarty K; Cornelissen B; Scollard DA; Done SJ; Chun K; Reilly RM Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):81-93. PubMed ID: 18712381 [TBL] [Abstract][Full Text] [Related]
5. Spectral Photon-Counting Molecular Imaging for Quantification of Monoclonal Antibody-Conjugated Gold Nanoparticles Targeted to Lymphoma and Breast Cancer: An Moghiseh M; Lowe C; Lewis JG; Kumar D; Butler A; Anderson N; Raja A Contrast Media Mol Imaging; 2018; 2018():2136840. PubMed ID: 30662379 [TBL] [Abstract][Full Text] [Related]
6. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342 [TBL] [Abstract][Full Text] [Related]
7. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729 [TBL] [Abstract][Full Text] [Related]
8. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017 [TBL] [Abstract][Full Text] [Related]
9. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Liu J; Li J; Rosol TJ; Pan X; Voorhees JL Phys Med Biol; 2007 Aug; 52(16):4739-47. PubMed ID: 17671332 [TBL] [Abstract][Full Text] [Related]
10. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Chen KT; Lee TW; Lo JM Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002 [TBL] [Abstract][Full Text] [Related]
11. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer. Chen H; Wang L; Yu Q; Qian W; Tiwari D; Yi H; Wang AY; Huang J; Yang L; Mao H Int J Nanomedicine; 2013; 8():3781-94. PubMed ID: 24124366 [TBL] [Abstract][Full Text] [Related]
12. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
13. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070 [TBL] [Abstract][Full Text] [Related]
14. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates. Razumienko E; Dryden L; Scollard D; Reilly RM Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982 [TBL] [Abstract][Full Text] [Related]
15. Single-antibody, targeted nanoparticle delivery of camptothecin. Han H; Davis ME Mol Pharm; 2013 Jul; 10(7):2558-67. PubMed ID: 23676007 [TBL] [Abstract][Full Text] [Related]
16. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661 [TBL] [Abstract][Full Text] [Related]
17. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347 [TBL] [Abstract][Full Text] [Related]
18. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314 [TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. Hu J; Ljubimova JY; Inoue S; Konda B; Patil R; Ding H; Espinoza A; Wawrowsky KA; Patil C; Ljubimov AV; Black KL PLoS One; 2010 Apr; 5(4):e10108. PubMed ID: 20419092 [TBL] [Abstract][Full Text] [Related]
20. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. Ashton JR; Gottlin EB; Patz EF; West JL; Badea CT PLoS One; 2018; 13(11):e0206950. PubMed ID: 30408128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]